Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): HQ2216 obtains clinical trial approval.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that its wholly-owned subsidiary, Hangzhou Bio-Sincerity Pharma-Tech (Zhuhai Hengqin) Co., Ltd., recently received a clinical trial approval notification from the National Medical Products Administration (NMPA). The company's independently developed drug HQ2216 will undergo clinical trial research for the prevention of stress-induced ulcer bleeding in critically ill patients.